SCNX Scienture Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1382574 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY127.4%
TTM net income YoY-96.3%
TTM EPS YoY144.2%
Revenue 3-yr CAGR-24.9%
Net income 3-yr CAGR—
Margins
Gross margin78.5%
Operating margin-2,788.5%
Net margin-2,715.9%
FCF margin—
EBITDA margin-2,662.9%
Returns
ROE-57.1%
ROA-47.1%
ROIC (approx.)-47.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets32.6%
Debt / equity0.00x
Current ratio1.10x
Interest coverage-25.26x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-30.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.25M | $343,639 | $56,325 | -$168,699 | $590,050 | $0 | $10,258 | $53,083 |
| Cost of revenue | $234,628 | $7,860 | $2,475 | $75,113 | $15,429 | $0 | $9,585 | $50,258 |
| Gross profit | $1.02M | $335,779 | $53,850 | -$243,812 | $574,621 | $0 | $673 | $2,825 |
| R&D expense | $1.39M | $1.17M | $793,984 | $368,698 | $169,344 | $843,549 | $574,679 | $982,707 |
| SG&A expense | $2.93M | $368,790 | $1.07M | $1.48M | $2.17M | $2.93M | $1.36M | $1.39M |
| Operating income | -$5.72M | -$2.70M | -$3.51M | -$29.50M | -$4.36M | -$5.16M | -$3.57M | -$4.21M |
| Interest expense | $377,947 | $269,785 | $37,019 | $955,499 | $1.80M | $653,493 | $670,784 | $1.01M |
| Pretax income | — | — | — | -$30.12M | -$3.61M | -$6.72M | -$3.06M | -$7.34M |
| Net income | -$6.01M | -$2.82M | -$3.40M | -$28.12M | -$3.61M | -$6.72M | -$3.06M | -$7.16M |
| EBITDA | -$5.26M | -$2.24M | -$3.06M | -$29.01M | -$4.36M | -$5.16M | -$3.57M | -$4.21M |
| EPS (basic) | -3.76 | -0.07 | -0.08 | — | -4.76 | -0.48 | -0.33 | — |
| EPS (diluted) | -3.76 | -0.07 | -0.08 | — | -4.76 | -0.48 | -0.33 | — |
| Weighted avg. shares (diluted) | 1.60M | 39.62M | 40.63M | — | 758,306 | 14.14M | 9.43M | — |
| Banking | ||||||||
| Deposits | — | $2.21M | — | $1.18M | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.75M | $8.19M | $3.54M | $6.66M | $355,692 | $15,391 | $2.05M | $308,096 |
| Receivables | $2.22M | $385,313 | $722,545 | $731,328 | $590,050 | — | $3,734 | $11,106 |
| Inventory | $998,109 | $203,074 | $210,934 | $213,408 | $234,521 | — | — | — |
| Current assets | $8.83M | $9.20M | $4.77M | $7.92M | $1.42M | $856,625 | $7.83M | $6.31M |
| PP&E, net | $14,500 | $14,500 | $15,000 | $15,500 | $16,000 | $16,500 | $17,000 | $17,500 |
| Goodwill | — | — | — | — | $21.37M | $21.37M | $21.37M | $21.37M |
| Intangibles | $69.61M | $70.07M | $70.52M | $70.97M | $76.40M | $76.40M | $76.40M | $76.40M |
| Total assets | $87.18M | $87.73M | $80.66M | $84.18M | $84.18M | $84.18M | $84.18M | $104.85M |
| Current liabilities | $8.06M | $3.03M | $2.80M | $2.74M | $7.35M | $7.69M | $7.46M | $7.91M |
| Long-term debt | — | — | — | — | $2.00M | $3.58M | $3.09M | $2.90M |
| Total debt | — | — | — | — | $2.00M | $3.58M | $3.09M | $2.90M |
| Total liabilities | $28.44M | $23.63M | $13.84M | $14.06M | $22.16M | $26.43M | $25.20M | $25.78M |
| Shareholders' equity | $58.74M | $64.10M | $66.82M | $70.12M | $82.67M | $77.86M | $81.16M | $79.07M |
| Net debt | — | — | — | — | $1.64M | $3.56M | $1.04M | $2.59M |
| Shares outstanding | 1.79M | 41.06M | 40.63M | 1.63M | 23.13M | 16.13M | 12.52M | 8.75M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.46M | -$3.13M | -$2.92M | -$5.18M | -$3.21M | -$2.03M | -$2.96M | -$2.91M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$2.91M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $39,562 | $10.79M | -$200,000 | $11.48M | $3.55M | $0 | $4.70M | $2.79M |
| Depreciation & amortization | $460,167 | $461,571 | $454,346 | $490,281 | $500 | $500 | $500 | $0 |
| Stock-based compensation | $126,948 | $103,457 | $102,320 | $248,459 | $1.66M | $162,437 | $437 | $437 |
| Dividends paid | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 54 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.